Bio Plus Co., Ltd

Total Valuation

Bio Plus Co., Ltd carries a market capitalization of 242.16B, placing it among publicly traded companies globally. Its enterprise value stands at 346.79B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Bio Plus Co., Ltd currently has 61.54M shares outstanding.

Valuation Ratios

Bio Plus Co., Ltd trades at a trailing price-to-earnings ratio of 20.87. The price-to-sales ratio is 3.09, and the price-to-book ratio stands at 2.36.

Enterprise Valuation

On an enterprise value basis, Bio Plus Co., Ltd trades at an EV/EBITDA multiple of 25.57 and an EV/FCF ratio of 7.44. The EV/Sales ratio of 3.67 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 25.57 provides insight into valuation relative to core operating earnings.

Financial Position

Bio Plus Co., Ltd maintains a current ratio of 0.94, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 32.18, indicating elevated leverage, while an interest coverage ratio of 43.72 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Bio Plus Co., Ltd has paid -2.13B in income taxes, reflecting an effective tax rate of 38.53.

Stock Price Statistics

Bio Plus Co., Ltd's stock has declined approximately -45.34722% over the past 52 weeks. The 50-day moving average sits at 5,053.10, while the 200-day moving average is 5,468.80.

Income Statement

Over the trailing twelve months, Bio Plus Co., Ltd generated 94.42B in revenue and converted that into 14.00B in net income, yielding earnings per share of 305.14. EBITDA reached 13.56B, while operating income came in at 13.56B.

Balance Sheet

Bio Plus Co., Ltd holds 30.74B in cash and equivalents against 64.05B in total debt, resulting in a net debt position of 40.32B. Total book value stands at 124.00B, with working capital of -4.73B providing operational flexibility.

Cash Flow

Bio Plus Co., Ltd produced 14.36B in operating cash flow over the past twelve months. After subtracting -31.92B in capital expenditures, free cash flow totaled -17.55B - equivalent to -293.61 per share.

Margins

Bio Plus Co., Ltd operates with a gross margin of 67.45, reflecting its pricing power and cost economics. The operating margin of 14.37 and net profit margin of 14.82 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Bio Plus Co., Ltd's most recent stock split took place on November 23, 2022 with a 1:4 split ratio.

Scores

Bio Plus Co., Ltd posts an Altman Z-Score of 2.69, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.